800nok
3,9 %
Date:2025-11-03Time:18:00:00Latest report:Q2-2025List:Oslo GrowthTicker:LYTIX
Market Cap:545 mnokEnterprise Value:508 mnokNet Sales:0,61 mnokEarnings:-72,6 mnokEmployees:0ISIN:NO0010405780

Ratios

10-year key figure history for Lytix Biopharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Lytix Biopharma with index and moving average MA50 and MA200.

Stockprice:8,00
MA50:7,61
MA200:7,16
Price/MA200:11,8 %
RSI (14):57,2
Price/MA50:5,2 %

Description

Lytix Biopharma is a clinical-stage biotechnology company developing cancer immunotherapies. The company's technology is based on research into antimicrobial peptides, a defense against pathogens. Lytix Biopharma's lead product, LTX-315, is an oncolytic peptide with the aim of personalizing immunotherapy. The company conducts its research and operations in Oslo, Norway.

Biotechnology